Radiopharm Theranostics news

Sydney, Australia - November 23, 2022 - Radiopharm Theranostics (ASX:RAD), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that Imperial College London has released additional data related to the F-18 Pivalate (RAD 101) Phase 2a imaging trial in patients with brain metastases.

High contrast images (see below) were seen at 60 minutes after radiotracer injection. The images showed the maximum standard

Radiopharm Theranostics Limited (ASX:RAD, RAD or the Company), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the successful completion of the retail component of the fully underwritten 1 for 3.55 prorata accelerated non-renounceable entitlement offer (Entitlement Offer) announced by the Company on 19 October 2022. New fully paid shares under the Entitlement Offer (New Shares) will be issued at a price of

bydney, Australia - November n, lull — Kaaiopnarm I neranostics (A:>a:kauj, a aeveioper or a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce agreement with Australia`s Nuclear Science and Technology Organisation (ANSTO) to supply the Company with isotope non-carrier-added lutetium-177 (Lu-177) for its trials in Australia.

The isotope will be used by in combination with Radiopharm`s propriety nanobody in a P

Radiopharm Theranostics Limited (ASX:RAD, "RAD" or the "Company"), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, refers to its fully underwritten non-renounceable entitlement issue originally announced on 19 October 2022, of 1 New Share for every 3.55 Existing Shares held by Eligible Shareholders at an Offer Price of $0.14 per New Share (together with one free attaching New Option for every New Share issued) (with full details